Newsroom FDA Accepts NDA for Glaukos’ Corneal Cross Linking Drug Treatment
February 25, 2025

FDA Accepts NDA for Glaukos’ Corneal Cross-Linking Drug Treatment

Glaukos’ Epioxa eyes FDA approval as the first non-invasive cross-linking therapy for keratoconus.  Glaukos Corporation (California, USA) announced yesterday that…

Discover our fascinating content at issuu

explore